Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

In May, Sarepta’s stock dropped further after it lowered its 2025 revenue guidance from $2.9 billion - $3.1 billion to $2.3 billion - $2.6 billion. This was attributed to ELEVIDYS.

On June 18, TD Cowen downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock to “Hold” from “Buy,” reducing the price objective to $24 from the prior target of $62, as reported by ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died. The patient was being treated for Duchenne muscular dystrophy, and ...

Sarepta Therapeutics (SRPT) stock faces downgrades as it suspends 2025 revenue guidance amid safety concerns for its Duchenne gene therapy. Read more here.

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...

Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $102.54, accompanied by a high estimate of $202.00 and a low estimate of $40.00. A ...

On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential ...